Sign In
Buy NRIX
$18.86
+0.210 (+1.13%)
At Close: Jun 23, 2026
Nurix Therapeutics Deal With Roche Is Worth Betting On
09:48am, Thursday, 11'th Jun 2026
Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the stock as a whole. Similarly, this deal helps validate NRIX's bexobrutideg and its potential as a broade
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median prog
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
09:59am, Tuesday, 09'th Jun 2026
Nurix Therapeutics, Inc. remains a Strong Buy as bexobrutideg advances in pivotal r/r CLL trials and secures a transformative $2.3B global partnership with Roche. Bexobrutideg demonstrates superior ef
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
07:26am, Tuesday, 09'th Jun 2026
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
02:35pm, Monday, 08'th Jun 2026
Roche Holding AG (RHHBY) has agreed to pay Nurix Therapeutics (NRIX) as much as $2.3 billion for rights to bexobrutideg, an experimental pill targeting certain
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
12:46pm, Monday, 08'th Jun 2026
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
10:08am, Monday, 08'th Jun 2026
Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
10:06am, Monday, 08'th Jun 2026
Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg.
Nurix Therapeutics Stock Pops on Roche Partnership
09:45am, Monday, 08'th Jun 2026
Nurix Therapeutics Inc (NASDAQ:NRIX) stock is up 15.7% to trade at $16.94, after the biotech company announced a collaboration and licensing agreement with Roche for blood cancer treatment bexobrutid
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
09:26am, Monday, 08'th Jun 2026
Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock is up during Monday's premarket session as the company collaborates with Roche Holdings AG (OTC:RHHBY) to co-develop and co-commercialize bexobrutideg, an
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
03:51am, Monday, 08'th Jun 2026
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
01:47am, Monday, 08'th Jun 2026
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche's oncology pipeline and offers potential indica
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clini
